Daiichi Sankyo Co., Ltd. (DSKYF)
21.85
-0.92
(-4.06%)
USD |
OTCM |
Dec 10, 15:50
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 40.45B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -19.97% |
| Valuation | |
| PE Ratio | 21.78 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.080 |
| Price to Book Value | 3.614 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.2521 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1217 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 53.03% |
Profile
| Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan. |
| URL | https://www.daiichisankyo.co.jp |
| Investor Relations URL | https://www.daiichisankyo.com/investors/ |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jan. 29, 2026 (est.) |
| Last Earnings Release | Oct. 31, 2025 |
| Next Ex-Dividend Date | Mar. 31, 2026 |
| Last Ex-Dividend Date | Sep. 30, 2025 |
Ratings
Profile
| Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan. |
| URL | https://www.daiichisankyo.co.jp |
| Investor Relations URL | https://www.daiichisankyo.com/investors/ |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jan. 29, 2026 (est.) |
| Last Earnings Release | Oct. 31, 2025 |
| Next Ex-Dividend Date | Mar. 31, 2026 |
| Last Ex-Dividend Date | Sep. 30, 2025 |